Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Melanoma presents significant therapeutic challenges, with current treatments like targeted drugs and immune checkpoint inhibitors facing limitations due to resistance and toxicity.
• Nanotechnology offers potential solutions for improving drug delivery and achieving greater tumor selectivity in cancer treatment.

Purpose of the Study:

• To explore the potential of liposomes as nanocarriers for enhancing melanoma therapy.
• To evaluate the advantages of liposomal drug formulations in overcoming limitations of conventional melanoma treatments.

Main Methods:

• Review of experimental models and existing literature on liposomal drug delivery systems for melanoma.
• Analysis of liposome characteristics, including their ability to carry diverse molecules and surface modification capabilities.
• Assessment of liposomal formulations for targeted delivery and combination therapy approaches.

Main Results:

• Liposomes can encapsulate both hydrophilic and hydrophobic drugs, offering versatility in treatment options.
• Surface modification of liposomes allows for targeted delivery to melanoma cells, potentially reducing off-target effects.
• Liposomal formulations demonstrated increased drug concentration in tumor tissue and reduced distribution to healthy organs in experimental models.
• Liposomes can serve as a single delivery system for combining multiple therapeutic agents, including chemotherapies, immunomodulators, and nucleic acids.

Conclusions:

• Liposomes represent a promising nanocarrier for advancing melanoma therapy, addressing limitations of current treatments.
• Further development is needed to overcome challenges in formulation stability and large-scale production for clinical translation.
• Liposomes are a key development in oncologic nanotechnology, paving the way for safer and more effective melanoma treatments.